J&J opts out of licensing Genmab’s Darzalex challenger after look at phase 1/2 data
Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter company to discontinue development of the program. | Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody,
Johnson and Johnson will not exercise worldwide license option for HexaBody-CD38, says Genmab
Genmab A/S (Nasdaq: GMAB) said on Monday that Johnson & Johnson (J&J) has decided not to exercise its option to obtain a worldwide license for the development, manufacturing, and commercialization of HexaBody-CD38.
Genmab says J&J not exercising option on HexaBody-CD38
Genmab (GMAB) announced that Johnson & Johnson (JNJ) has decided that it will not exercise its option to receive a worldwide license to
Genmab stock tumbles after J&J opts out of licensing deal
The decision comes after Genmab provided J&J with data from a clinical proof-of-concept study, which included a head-to-head comparison with DARZALEX FASPRO® (daratumumab and hyaluronidase fihj) in patients with relapsed or refractory multiple myeloma.
Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38
Genmab A/S (Nasdaq: GMAB) announced today that Johnson & Johnson (J&J) has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 (GEN3014).
Genmab Shares Fall After J&J Drops Blood-Cancer Treatment Option
Genmab shares fell on Monday after the company said it would end the development of blood-cancer treatment HexaBody-CD38 because Johnson & Johnson won't exercise its option to license it.
pharmaphorum2d
J&J defends Darzalex with FDA approval for faster dosing
Last year, J&J licensed a follow-up to Darzalex from Genmab, HexaBody-CD38, that it says could be used in Darzalex-resistant patients as well as in other cancer indications beyond myeloma ...
Seeking Alpha20d
Genmab: Positive 2025 Outlook, Johnson & Johnson's Decision Coming Soon
The stock has rebounded since the earnings report, but it was under pressure since my previous update as investors and traders contemplate the fate of GEN3014, the next-generation CD38 HexaBody on ...
Genmab Stops Blood Cancer Treatment Development After J&J Won't License It
Genmab has stopped clinical development of a blood cancer treatment after Johnson & Johnson decided it won't exercise its option to license it.
pharmaphorum3d
Janssen combines Darzalex with COVID-19 drug in new multiple myeloma submission
Last year, J&J licensed a follow-up to Darzalex from Genmab, HexaBody-CD38, that it says could be used in Darzalex-resistant patients as well as in other cancer indications beyond myeloma ...
Hosted on MSN25d
Leerink raises Genmab stock rating to outperform, PT steady at $27
The upgrade reflects a positive long-term outlook despite expectations that Johnson & Johnson (JNJ) is unlikely to opt-in for GEN3014 (Hexabody-CD38), a decision anticipated within the first ...